SavedAdd your journal

Journals / GORM:Gynecology Obstetrics & Reproductive Medicine / 2020 / Cilt: 26 - Sayı: 3

The Screening of Antiphospholipid Antibodies in Obstetric Antiphospholipid Syndrome-Like Events: A Regional Perspective

Önder ÖNEN
Füsun VAROL
Pages
162–165
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Besides, long persistence of antiphospholipid-M positivity in these placenta-mediated disorders may make sense in terms of trophoblastic damage

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Obstetric antiphospholipid antibody syndrome is clinically recognized by adverse obstetric outcomes.
📊
Key Findings & Data:Obstetric antiphospholipid antibody syndrome-like adverse obstetric outcomes with single (n=108) and repeat (n=79) documented antiphospholipid antibody titers were evaluated.
💡
Conclusion & Impact:Besides, long persistence of antiphospholipid-M positivity in these placenta-mediated disorders may make sense in terms of trophoblastic damage
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

OBJECTIVE: Obstetric antiphospholipid antibody syndrome is clinically recognized by adverse obstetric outcomes. To determine which antibody level best corresponds to the risk of these clinical outcomes is difficult. Obstetric antiphospholipid antibody syndrome-like adverse obstetric outcomes with single (n=108) and repeat (n=79) documented antiphospholipid antibody titers were evaluated. STUDY DESIGN: Serum samples of 108 Obstetric antiphospholipid antibody syndrome cases and 50 healthy gestational matched controls with no history of thrombosis and congenital anomalies were subjected to testing for antiphospholipid antibodies with ELISA after the events. Of this obstetric antiphospholipid antibody syndrome group, only 79 cases underwent repeat testing within 12 weeks. Quantitative data were described by values and percentages at the levels of (>10) and (>40 U). RESULTS: By one documented antiphospholipid test, the mean values of anticardiolipin, and anti-β2 glycoprotein1 (aβ2GP1) of obstetric antiphospholipid antibody syndrome versus controls were significantly different (p 40 U of antiphospholipid antibody was only 8 (18.60%). CONCLUSION: Not all obstetric antiphospholipid antibody syndrome associated pregnancy morbidities may own high (>40U) antiphospholipid antibody titers, but low antiphospholipid antibodies (>10U) also accompany to this clinical picture. Obstetric antiphospholipid antibody syndrome should always be taken into account clinically prior to laboratory findings. Besides, long persistence of antiphospholipid-M positivity in these placenta-mediated disorders may make sense in terms of trophoblastic damage

🔖

Cite This Article

ÖNEN, Ö., VAROL, F. (2020). The Screening of Antiphospholipid Antibodies in Obstetric Antiphospholipid Syndrome-Like Events: A Regional Perspective. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 26 - Sayı: 3, 162–165. https://ajindex.com/articles/226972

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement onan update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Hae most. 2006;4(2):295-306. DOI: 10.1111/j.1538-7836.2006. 01753.x 2. Roubey RA. Autoantibodies to phospholipids-bindingplasma proteins: a new view of lupus anticoagulants andother “antiphospholipid” antibodies. Blood. 1994;84(9): 2854-67 PMID:7949161 3. Mekinian A, Loire-Berson P, Nicaise-Roland P, Lachas - sinne E, Stirnemann J, Boffa MC, et al. Outco mesand treatment of obstetrical antiphospholipid syndrome inwomen with low antiphospholipid antibody levels. JReprod Immunol. 2012;94(2):222-6 DOI:10. 1016/j.jri. 2012.02.004 4. Boffa MC, Boinot C, De Carolis S, Rovere-Querini P, Aurousseau MH, Allegri F, et al. Laboratory criteria of theobstetrical antiphospholipid syndrome. Data from a multi-centric prospective European women cohort. ThrombHaemost. 2009;102(1);225-8. DOI:10.1160/TH 09-01-0043 5. de Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IE, et al. The association between circulating an-tibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J ThrombHaemost. 2009;7(11):1767-73. DOI: 10.1111/j. 1538-7836.2009.03588.x 6. Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, Mercier E, Marchetti T, Balducchi JP, et al. Compara ti - veincidence of pregnancy outcomes in treated obstetric an-tiphospholipid syndrome: the NOH-APS observationalstudy. Blood. 2014;123(3):404-13. DOİ: 10.1182/ blood-2013-08-522623 7. Opatrny L, David M, Kahn SR, Shrier I, Rey E. As - so ciation between antiphospholipid antibodies and re-current fetal loss in women without autoimmune disease:a metaanalysis. J Rheumatol. 2006;33(11):2214-21. PMID: 17014001 8. Drakeley AJ, Quenby S, Farquharson R. Mid-trimesterloss- appraisal of a screening protocol. Hum Reprod. 1998;13(7):1975-80. DOI: 10.1093/humrep/13.7.1975 9. Galarza-Maldonado C, Kourilovitch MR, Pérez-Fernán - dez OM, Gaybor M, Cordero C, Cabrera S, et al.Obstetric antiphospholipid syndrome. Autoimmun Rev.2012;11(4): 288-95. DOI: 10.1016/j.autrev.2011.10.006 10. Levy RA, Dos Santos FC, de Jesús GR, de Jesús NR. Antiphospholipid antibodies and antiphospholipid syndrome during pregnancy: diagnostic concepts. Front Im munol. 2015;6:205-9. doi: 10.3389/fimmu. 2015.00205 11. Simchen MJ, Dulitzki M, Rofe G, Shani H, Langevitz P,Schiff E, et al. High positive antibody ti